drugset / Trial / NCT03387046
A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study was to evaluate the improvement in spontaneous recovery from clinical deficits at the time of an acute relapse in RR-MS participants already receiving interferon (IFN) beta 1a with D-aspartate (versus placebo) as add-on therapy.
Timeline
- Start
- 2018-03-26
- Primary completion
- 2019-01-11
- Completion
- 2019-01-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | D-Aspartate | Small molecule | 2660 mg | Oral |
| Background | IFN beta-1a | Protein / enzyme biologic | 44 ug | Subcutaneous |
| Background | Methylprednisolone | Other / unclassified | 1000 mg | Intravenous |